Non-transplant surgical therapy options of heart failure

S Neragi-Miandoab1

  • 1Department of Cardiothoracic Surgery Montefiore Medical Center Albert Einstein College of Medicine Bronx, NY, USA - siyamekneragi@yahoo.com.

Minerva Cardioangiologica
|November 26, 2014
PubMed

Insights

Congestive heart failure (CHF) is a major cause of death. This overview focuses on non-transplant surgical treatments to manage CHF progression and improve patient outcomes.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery

Background:

  • Congestive heart failure (CHF) is a significant cause of cardiovascular morbidity and mortality, with a 5-year mortality rate of 50%.
  • The economic burden of CHF is substantial, driven by increased hospitalizations, advanced device implantation, and end-of-life care.
  • CHF progression involves detrimental left ventricular remodeling, necessitating strategies to halt or reverse these changes.

Purpose of the Study:

  • To provide an overview of non-transplant surgical management options for congestive heart failure.
  • To highlight advancements in therapies and devices for managing CHF.
  • To discuss strategies aimed at stopping or reversing left ventricular remodeling in heart failure.

Main Methods:

  • Review of current literature on surgical interventions for CHF.
  • Analysis of advancements in mechanical circulatory support, including left ventricular assist devices (LVADs) and total artificial hearts.
  • Discussion of established and novel therapeutic strategies for heart failure management.

Main Results:

  • Medical management, mechanical circulatory support, cardiac resynchronization therapy, and biventricular pacemakers are established treatments.
  • Mechanical support devices like LVADs have significantly reduced mortality in patients awaiting transplantation.
  • Non-transplant surgical options offer viable alternatives for managing CHF progression.

Conclusions:

  • The management of CHF has evolved significantly with new therapies and assist devices.
  • Non-transplant surgical options play a crucial role in improving outcomes for CHF patients.
  • Continued innovation in surgical and device-based therapies is essential for addressing CHF mortality and morbidity.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
614
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
594
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
732
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
814
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
651